Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 5 changes by month →When this page itself was last checked or edited.
High objective and complete response rates in relapsed follicular lymphoma with durable remissions; accelerated approval in March 2021.
Lenalidomide plus rituximab substantially lengthened progression-free survival compared with rituximab alone; approved in May 2019.
Five-year event-free survival 68 per cent with chlorambucil and rituximab against 51 and 50 per cent for either alone, with five-year overall survival about 90 per cent in all three arms.
4 Gy was not non-inferior to 24 Gy for local control: five-year local progression-free rate 89.